14 completed. 14 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 14 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow SOC: new trials by email Literature Review of SOC trials Research Report on SOC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Telitacicept on Antibody Titers in Primary APS Patients Telitacicept+SOC, SOC - Antiphospholipid Syndrome (APS) | Phase 2 | Completed | Ruijin Hospital | 20 | 2023-12-01 | 2026-01-20 |
| A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS INM004, SoC - Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease | Phase 2 | Completed | Inmunova S.A. | 57 | 2022-10-06 | 2023-08-21 |
| Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection Firazyr, SoC - COVID-19 Pneumonia | Phase 2 | Completed | Sebastian Videla | 73 | 2021-04-12 | 2022-08-03 |
| Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 Ruconest - Confirmed Coronavirus Disease | Phase 2 | Completed | Pharming Technologies B.V. | 38 | 2020-11-30 | 2024-02-16 |
| Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 Silmitasertib, SOC - Covid19 | Phase 2 | Completed | Senhwa Biosciences, Inc. | 20 | 2020-11-30 | 2025-01-16 |
| A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients Bemcentinib, SoC - COVID-19 | Phase 2 | Completed | BerGenBio ASA | 115 | 2020-10-20 | 2024-10-16 |
| Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients Blood and derivatives., Standard of Care - COVID-19 | Phase 2 | Completed | Cristina Avendaño Solá | 350 | 2020-04-03 | 2024-12-02 |
| A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Sotatercept, SOC - Pulmonary Arterial Hypertension | Phase 2 | Completed | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 21 | 2019-04-19 | 2024-08-27 |
| A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) Placebo, Sotatercept, SOC - Pulmonary Arterial Hypertension | Phase 2 | Completed | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 106 | 2018-06-13 | 2023-04-19 |
| Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) CLBS12, SOC - Critical Limb Ischemia, Buerger Disease | Phase 2 | Completed | Lisata Therapeutics, Inc. | 33 | 2017-11-01 | 2024-10-09 |
| Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery. D-PLEX, Open heart surgery - Postoperative Wound Infection Superficial Incisional, Postoperative Wound Infection Deep Incisional Surgical Site | Phase 1 / Phase 2 | Completed | PolyPid Ltd. | 81 | 2016-10-12 | 2026-04-13 |
| ODYSSEY (PENTA 20) Dolutegravir, Standard of Care - HIV Infection | Phase 2 / Phase 3 | Completed | PENTA Foundation | 792 | 2016-09-20 | 2025-07-29 |
| Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children DTG +DRV/r, SOC - HIV Infection | Phase 2 / Phase 3 | Completed | PENTA Foundation | 318 | 2016-06-01 | 2021-03-30 |
| Tocilizumab (TCZ) in New-onset Type 1 Diabetes Tocilizumab (TCZ), Placebo, Standard of Care - Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 136 | 2015-03-12 | 2021-09-08 |
COVID-19 (3) · HIV Infections (2) · Pulmonary Arterial Hypertension (2) · Antiphospholipid Syndrome (1) · Chronic Limb-Threatening Ischemia (1) · Coronavirus Infections (1) · Diabetes Mellitus, Type 1 (1) · Hemolytic-Uremic Syndrome (1) · Thromboangiitis Obliterans (1)
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (2) · PENTA Foundation (2) · BerGenBio ASA (1) · Cristina Avendaño Solá (1) · Inmunova S.A. (1) · Lisata Therapeutics, Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Pharming Technologies B.V. (1) · PolyPid Ltd. (1) · Ruijin Hospital (1) · Sebastian Videla (1) · Senhwa Biosciences, Inc. (1)
Spain (5) · United States (5) · South Africa (3) · United Kingdom (3) · Argentina (2) · Australia (2) · France (2) · Germany (2) · Israel (2) · Portugal (2) · Thailand (2) · Uganda (2) · Brazil (1) · China (1) · India (1)
Antonio Ramos, MD, PhD (1) · Carla Greenbaum (1) · Chris P. Recknor, MD (1) · Diana Gibb (1) · Erez V. Kachel, MD (1) · Fernando Goldbaum, PhD (1) · Hani Gabra (1) · Inmaculada Casas Flecha, PharmD, PhD (1) · Jane Buckner, M.D. (1) · Jonathan Bernstein, MD (1) · Jonathan Lu, MD (1) · Kristen K Buck, MD (1)
PMID 27629486, PMID 32763217, PMID 33446115, PMID 33472681, PMID 33789009, PMID 34013969, PMID 34473652, PMID 34747368, PMID 34817414, PMID 34965338, PMID 35413921, PMID 35868341, PMID 36041750, PMID 36055295, PMID 36610464, PMID 36734509, PMID 37162745, PMID 37304494, PMID 37766505, PMID 38572639, PMID 39978387, PMID 40035659, PMID 41579881, PMID 41757982, PMID 42246435
2014 (1), 2017 (1)